Two ongoing Phase 2 clinical trials of CPX-351 to be showcased

Sep 4 2009

Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the Thomas Weisel Partners 2009 Healthcare Conference in Boston.

Mr. Jackson will provide a corporate overview and an update on the company's progress with two ongoing Phase 2 clinical trials of CPX-351 in newly diagnosed acute myeloid leukemia (AML) patients and first-relapse AML patients. The presentation will be given on Thursday, September 10, 2009 at 1:30pm EDT in the Blaxton Room of the Four Seasons Hotel.

Source:

http://www.celatorpharma.com

Posted in: Drug Trial News

Tags: , , , , , , , , , ,

Comments (0)

Suggested Reading

Study pinpoints how gut microbes boost the body's response to cancer immunotherapy
Using 3D-electron diffraction to determine the structure of Levocetirizine dihydrochloride
Pre- and post-surgical immunotherapy-based treatment significantly improved lung cancer outcomes
FAU and Insightec collaborate to use focused ultrasound to treat brain diseases
Research sheds light on the early cellular events that give rise to pancreatic cancer
High prevalence of galactagogue use among breastfeeding mothers in U.S.
Bridging the Gap between Academia and Industry: The Power of Collaboration in Life Sciences
ChatGPT provides higher quality and more empathetic responses to patient questions

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »
You might also like...
Researchers discover a key player in preventing 'insulin shock'